• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Orchard Therapeutics, UCLA land $20m for stem cell clinical trial

November 23, 2016 By Sarah Faulkner

Orchard Therapeutics, UCLA land $20m for stem cell clinical trialOrchard Therapeutics and researchers from the University of California Los Angeles Broad Stem Cell Research have been awarded $20 million from the California Institute for Regenerative Medicine’s governing to fund a clinical trial for adenosine deaminase deficiency.

The rare, inherited disorder is caused by mutations in a gene that encodes for adenosine deaminase. This results in a white blood cell deficiency and life-threatening infections. Without treatment, ADA-SCID is fatal within the 1st months of a person’s life.

More than 40 ADA-SCID patients have been treated around the world using autologous ex-vivo lentiviral gene therapy. All of the patients have survived and the therapy has safely restored patients’ immune function, according to the 2 groups.

The therapy uses a patient’s stem cells, removing the need for a matching stem cell donor. The stem cells are modified with a copy of the missing or faulty gene before being transplanted back into the patient.

“We are very grateful for this funding and for all the patients who have already gone through our clinical trials,” principal investigator Dr. Kohn said in prepared remarks.

“Funding from CIRM will allow UCLA and Orchard Therapeutics to accelerate the development program with ex-vivo autologous lentiviral gene therapy, which could potentially greatly benefit patients,” Orchard’s interim CEO Dr. Alexander Pasteur added.

Filed Under: Business/Financial News, Featured, Funding Roundup, Immunotherapy, Stem Cells Tagged With: Orchard Therapeutics, University of California Los Angeles

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS